An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy
Metrics: PDF 1565 views | HTML 1366 views | ?
Vanessa Szablewski3,4, Caroline Bret1,2,3, Alboukadel Kassambara1,2, Julie Devin2, Guillaume Cartron3,5,6, Valérie Costes-Martineau3,4 and Jérôme Moreaux1,2,3
1Department of Biological Hematology, CHU Montpellier, Montpellier, France
2Institute of Human Genetics, CNRS-UM UMR 9002, Montpellier, France
3University of Montpellier, UFR de Médecine, Montpellier, France
4Department of Biopathology, CHU Montpellier, Montpellier, France
5CHU Montpellier, Department of Clinical Hematology, Montpellier, France
6Montpellier University, UMR CNRS 5235, Montpellier, France
Jérôme Moreaux, email: email@example.com
Keywords: epigenetics; Diffuse large B cells lymphoma; prognostic value; gene expression profiling; targeted treatment
Received: May 30, 2017 Accepted: March 01, 2018 Published: April 10, 2018
Diffuse large B-cell lymphoma (DLBCL) is the most common form of lymphoma and shows considerable clinical and biological heterogeneity. Much research is currently focused on the identification of prognostic markers for more specific patients’ risk stratification and on the development of therapeutic approaches to improve the long-term outcome. Epigenetic alterations are involved in various cancers, including lymphoma. Interestingly, epigenetic alterations are reversible and drugs to target some of them have been developed. In this study, we demonstrated that the gene expression profile of epigenetic regulators has a prognostic value in DLBCL and identified pathways that could be involved in DLBCL poor outcome. We then designed a new risk score (EpiScore) based on the gene expression level of the epigenetic regulators DNMT3A, DOT1L, SETD8. EpiScore was predictive of overall survival in DLBCL and allowed splitting patients with DLBCL from two independent cohorts (n = 414 and n = 69) in three groups (high, intermediate and low risk). EpiScore was an independent predictor of survival when compared with previously described prognostic factors, such as the International Prognostic Index (IPI), germinal center B cell and activated B cell molecular subgroups, gene expression-based risk score (GERS) and DNA repair score. Immunohistochemistry analysis of DNMT3A in 31 DLBCL samples showed that DNMT3A overexpression (>42% of positive tumor cells) correlated with reduced overall and event-free survival. Finally, an HDAC gene signature was significantly enriched in the DLBCL samples included in the EpiScore high-risk group. We conclude that EpiScore identifies high-risk patients with DLBCL who could benefit from epigenetic therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.